公开(公告)号：US20070025997A1

公开(公告)日：2007-02-01

申请号：US11413566

申请日：2006-04-27

申请人： Usha Nagavarapu ,  David Shivak ,  Daniel Chin ,  Erik Foehr ,  Mirella Gonzalez-Zulueta

发明人： Usha Nagavarapu ,  David Shivak ,  Daniel Chin ,  Erik Foehr ,  Mirella Gonzalez-Zulueta

IPC分类号： A61K39/395 ,  C12Q1/68 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  A61K2039/505 ,  C07K16/2851 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57407

摘要： The present invention relates to the use of proteins that are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of therapeutic and imaging agents, which specifically bind to one or more of the identified brain tumor protein targets. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.

摘要翻译： 本发明涉及与正常脑组织相比，在原发性脑肿瘤组织中差异表达的蛋白质作为脑肿瘤治疗疗法的生物分子靶标的用途。 具体地，本发明涉及特异性结合一种或多种所鉴定的脑肿瘤蛋白靶标的治疗和显像剂的用途。 本发明还提供了用于本发明方法中给药的化合物和药学上可接受的组合物。 还提供了针对编码这些变体的剪接mRNA特异性的核酸探针和对新蛋白特异的亲和试剂。